-
Relugolix
- names:
Relugolix
- CAS号:
737789-87-6
MDL Number: - MF(分子式): C29H27F2N7O5S MW(分子量): 623.63
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM003718-5mg | 5mg | >98.0% | ¥ 1620.00 | ¥ 1620.00 | 2-3天 | ¥ 0.00 | ||
| YZM003718-1mg | 1mg | >98.0% | ¥ 910.00 | ¥ 910.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | |
| 英文别名 | |
| CAS号 | 737789-87-6 |
| Inchi | |
| InchiKey | |
| 分子式 Formula | C29H27F2N7O5S |
| 分子量 Molecular Weight | 623.63 |
| 溶解度Solubility | 生物体外In Vitro:DMSO溶解度50 mg/mL(80.18 mM;Need ultrasonic) |
| 性状 | |
| 储藏条件 Storage conditions | 粉末Powder: -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
Relugolix(CAS:737789-87-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
| 产品说明 | Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013. |
| Introduction | Relugolix is a novel, noneptide, orally active gonadotropineleasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK85 possesses higher affinity and potent antagonistic activity compared with TAK13. |
| Application1 | |
| Application2 | |
| Application3 |
Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.
target: GnRH [1]
IC50: 0.33 nM [1]
In vivo: In female knock-in mice, twice-daily oral administration of TAK-385 (100mg/kg) induces constant diestrous phases within the first week, decreases the uterus weight to ovariectomized levels and downregulated GnRH receptor mRNA in the pituitary after 4 weeks.[2]
【1】.MacLean DB et al. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males.
J Clin Endocrinol Metab. 2015 Dec;100(12):4579-87.
【2】.Nakata D et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014 Jan 15;723:167-74.
【2】.Nakata D et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014 Jan 15;723:167-74.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


